KOL Insight - Acute Myeloid Leukaemia

This report provides an in-depth analysis of the current and future treatment landscape for acute myeloid leukaemia (AML), focusing on targeted therapies. Based on insights from key opinion leaders across the USA and Europe, it examines the use and impact of therapies like venetoclax, FLT3 inhibitors, and IDH inhibitors. The report highlights the increasing role of combination therapies and the potential of new treatments, providing a detailed look at how the treatment algorithm is expected to evolve over the next five years. Gain valuable insights into these major findings and their implications for AML treatment strategies.

Key Questions Answered:

• How do KOLs use AbbVie/Roche's Venclexta/Venclyxto (venetoclax) in AML treatment?
• What are KOLs' views on Venclexta/Venclyxto combination therapies?
• How do KOLs utilize FLT3 inhibitors, and which agents are preferred?
• How are IDH inhibitors used in AML according to KOLs?
• What is the expert opinion on Jazz Pharmaceuticals' Vyxeos compared to standard chemotherapy?
• How do European KOLs use Inaqovi, and what is its potential in the US market?
• What are US KOLs' opinions on the approval and expected uptake of Revuforj (revumenib)?
• What do KOLs think of Iomab-B's potential and the Phase III SIERRA trial results?
• How do experts view the potential of pipeline agents like Zeltherva, Orca-T, and iadademstat?
• How is the AML treatment algorithm expected to evolve over the next five years?

Key Brands:

Partial List of Participating Experts:

• Director, Georgia Cancer Center at Augusta University, Augusta, GA
• Professor, Translational Science and Therapeutics Division, Fred Hutch Cancer Center, WA
• Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, TX
• Professor of Haematology, Faculty of Medicine & Health Sciences at the University of Nottingham, Nottingham, UK
• Associate Professor of Haematology in the Department of Biomedicine and Prevention at the University of Rome Tor Vergata, Italy
• Professor Clinician at the Centre Hospitalier Universitaire (CHU) Bordeaux, Universite Bordeaux, Bordeaux, France

Methodology

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.